AEM vs LYB

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

LYB exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a critical dividend payout ratio of 1146.81%. While the stock has seen a recent price rally, the underlying financials show negative profit margins, negative ROE, and contracting revenue growth (-25.33% Q/Q). The combination of bearish insider sentiment and a 0/100 technical trend suggests the current price is unsupported by operational reality. The company is currently operating as a dividend trap, paying out far more than it earns.